Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2013

View Archived Issues

Sofosbuvir regimen effective in HCV/HIV-coinfected patients

Salbutamol beneficial in patients with spinal muscular atrophy

First-in-human trial of a recombinant vesicular stomatitis virus HIV-1 Gag vaccine

Sihuan Pharmaceutical's application for clinical trial approval for pirotinib accepted in China

Mimetogen commences phase III MIM-D3 study for dry eye syndrome

ERP29 and LEF1 gene polymorphisms linked to cutaneous melanoma risk

Immunogenic biomarker for the diagnosis and prognosis of lung cancer

Defibrotide receives positive COMP opinion for prevention of GVHD

FDA accepts supplemental BLA filing for Xolair

Sorrento Therapeutics acquires resiniferatoxin for chronic pain

QR Pharma and UCLA receive grant to test Posiphen in models of traumatic brain injury

Oral formulation of teriparatide shows promise in healthy subjects

Topline results reported from phase II ofatumumab trial in relapsing-remitting MS

Novartis licenses ImmunoGen technology

Otsuka acquires Astex Pharmaceuticals

Vivus grants U.S. and Canadian marketing rights for Stendra to Auxilium Pharmaceuticals

Bexion Pharmaceuticals receives SBIR Bridge Award from NCI

ADN-1184 may improve behavioral and psychological symptoms of dementia

DSMB gives recommendations for phase IIb study of vintafolide in NSCLC

BioInvent and Bayer extend antibody collaboration

Hybrigenics acquires Imaxio's genomics unit

Boehringer Ingelheim seeks European approval for nintedanib in advanced NSCLC

Elan discloses new BACE1 inhibitors for Alzheimer's disease

State University of New Jersey reports discovery of RNA polymerase inhibitors

PTC Therapeutics patents new compounds for SMA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...